RxDoctor Payments Data

Stephanie Russ, DO

Family Medicine · Pendleton, INNPI 1629239355

Payments from drug & device makers

$2,732in general payments, 2019–2025

Across 184 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$588
  • AbbVie$345
  • Lilly USA, LLC$320
  • AstraZeneca$255
  • Amgen$183
  • Pfizer$156
  • plus $885 from 27 others

What the payments were for

  • Food & beverage$2,724100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,732 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$34,390
Medicare patients
116
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$105,810
JardianceEmpagliflozin27$42,127
OzempicSemaglutide23$40,015
TrulicityDulaglutide29$37,442
FarxigaDapagliflozin Propanediol17$22,766
Tresiba Flextouch U-200Insulin Degludec14$19,223
LinzessLinaclotide11$17,453
RybelsusSemaglutide13$16,099
Spiriva RespimatTiotropium Bromide15$14,901
ShingrixVaricella-Zoster Ge/As01b/Pf25$5,492
Breo ElliptaFluticasone/Vilanterol12$5,002
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,017
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$3,656
Vilazodone Hcl15$3,461
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$320$143,25287 claims
Novo NordiskOzempic, Rybelsus$588$56,11436 claims
AstraZenecaFarxiga$255$22,76617 claims
AbbVieLinzess, Synthroid$345$18,57224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Pendleton

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →